Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
(
1 selected
)
Type
Guidance (784)
Guidance programme
(
2 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (223)
COVID-19 rapid guidelines (3)
Diagnostics guidance (47)
Health technology evaluations (18)
Highly specialised technologies guidance (27)
Interventional procedures guidance (601)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (339)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (757)
Apply filters
Showing 11 to 20 of 784
Sort by
Date
Title
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Adalimumab and dexamethasone for treating non-infectious uveitis
TA460
26 July 2017
26 July 2017
Adalimumab for the treatment of adults with psoriasis
TA146
25 June 2008
25 June 2008
Adalimumab for treating moderate to severe hidradenitis suppurativa
TA392
22 June 2016
22 June 2016
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
TA455
12 July 2017
12 July 2017
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA715
14 July 2021
14 July 2021
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
TA375
26 January 2016
26 January 2016
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
TA195
25 August 2010
25 August 2010
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
TA96
22 February 2006
22 February 2006
Afamelanotide for treating erythropoietic protoporphyria
HST27
26 July 2023
26 July 2023
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
TA444
24 May 2017
24 May 2017
Previous page
1
Current page
2
3
4
…
79
Page
2
of
79
Next page
Results per page
10
25
50
All
Back to top